iRIS technology

The iRIS technology monitors the secondary structure-sensitive amide I band in the infrared region, which indicates the degree of misfolding of biomarker proteins, such as Aβ, in the case of AD. The misfolding of biomarker proteins in body fluids, such as cerebrospinal fluid and blood, mirrors neurodegenerative processes in the brain. This allows the determination of AD in a symptom-free stage using body fluids.

How it works

Antibodies, bound via silane on the surface of the internal reflection element (IRE), extract Aβ proteins from the blood. The IRE guides the IR beam through the ATR unit. The evanescent beam analyses the secondary structure distribution of biomarker proteins bound to the IRE surface. As more misfolded proteins dominate, the risk of developing clinical AD is increased. Blocking compounds prevent the non-specific binding of other blood components.

 

The measuring principle is visualised in this video at a time marker of 25 min:

Link: https://www.zdf.de/wissen/leschs-kosmos/gesunde-kranke-im-netz-der-diagnostik-100.html

©RUB

 

Early detection of Alzheimer’s is the first step towards successful therapy

Morbus Alzheimer’s, or just Alzheimer’s, is the most common form of dementia, a disease characterised primarily by memory loss and other cognitive abilities impairment. When these symptoms occur, the brain seem already irreversibly damaged.

Use aducanumab as early as possible

For successful treatment with the Alzheimer’s drug aducanumab, the early initiation of medication is crucial. The earlier the treatment is started, the more effectively the disease can be delayed, ideally even stopped, and the lower is the risk of having already incurred irreversible damage. Aducanumab can only stop the disease at an early stage, but cannot cure it. According to the current state of research, cognition seems successful only in the early, not yet demented stage of AD. Therefore, the detection of very early stages before clinical symptoms appears, and before dementia with irreversible damage has been established, are essential for a successful therapy response. iRIS offers a technology that makes it possible to detect high-risk patients and identify a therapeutically successful window, thus protecting people from the severe symptoms of the disease.

We thrive on enabling symptom-free “healthy people” at high risk for AD to live a long full life without dementia.

Testing reveals risk levels

The risk of developing the disease can be assessed using a simple traffic light system. Values in the green range correspond to a low risk, values in the yellow range correspond to an increased risk, and values in the red range correspond to a high risk of developing Alzheimer’s in the next 6 years. This assessment offers the advantage that more complex examinations can subsequently be carried out, and therapy can be initiated at an early stage.

High risk

Measures: Follow-up with further tests, initiation of preventive measures, such as “lifestyle change,” and individual therapy agreement (e.g., with aducanumab).

Medium risk

Measures: Follow-up with further tests, initiation of preventive measures, such as “lifestyle change,” and, if necessary, the start of therapy (e.g., with aducanumab).

No risk

Measures: Re-testing after 5 years at the latest

Benefits of early diagnosis

Molecular changes in the brain can be observed 15–20 years before the first clinical symptoms. Therefore, individuals with a high risk of developing clinical AD can be identified, and intervention can be started with delay at a symptom-free or mildly impaired stage.

Receive adequate medical support.

Be eligible for clinical research and help with, for example, therapy development.

Reduce risk through lifestyle change.

Planning for the future.

What we work on

Alzheimer’s

An early diagnosis for Alzheimer’s with iRIS.

Clinical studies

Finding the most effective medical drugs.

Therapy Support:

Directly observe the therapeutic effect.

What we work on

Alzheimer’s

An early diagnosis for Alzheimer’s with iRIS.

Clinical studies

Finding the most effective medical drugs.

Therapy Support:

Directly observe the therapeutic effect.